Therapy Areas: Hereditary Disorders
Boehringer Ingelheim commences enrolment for cystic fibrosis drug trial
18 October 2019 -

Germany-based Boehringer Ingelheim has enrolled the first patient in its Phase II clinical trial BALANCE-CFTM 1 to assess a new potential treatment for cystic fibrosis, a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time, it was reported yesterday.

The trial is to investigate how different doses of the compound, an inhaled epithelial sodium channel inhibitor, affect lung function compared to placebo when added to the standard of care in adults and adolescents with cystic fibrosis. The inhaled epithelial sodium channel inhibitor is intended to treat patients with all types of cystic fibrosis mutations. It is inhaled through the Respimat1, which is the company's platform inhaler.

Dr Kay Tetzlaff, head of Medicine, Therapeutic Area Inflammation, Boehringer Ingelheim, said, 'We are pleased to enrol our first patient into this Phase II trial, and we hope our ENaC inhibitor will be proven to help people affected by cystic fibrosis. Boehringer Ingelheim is committed to researching new treatments that address serious unmet needs. We are hopeful that this treatment, along with its delivery method, will make an important difference for patients affected by this debilitating condition.'

Login
Username:

Password:


Related Headlines